Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Shield Therapeutics Plc
November 2024 Investor Forum
21st Nov 2024
Custodian Property Income REIT plc
November 2024 Investor Forum
20th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
105: Finding the venture opportunity in the energy transition | Reuben Wilcock of Blackfinch Ventures
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
Incanthera Ltd
Life Sciences
Solid progress since listing
By
Dr Martin Hall
08 Dec 2020
Arix Bioscience
Life Sciences
Artios attracts Merck KGaA in deal up to $7bn
By
Dr Martin Hall
07 Dec 2020
Stay up-to-date with the latest research
Sign up to our newsletter
Arix Bioscience
Life Sciences
Hitting the jackpot
By
Dr Martin Hall
06 Nov 2020
Tissue Regenix
Life Sciences
Funded through to profitability
By
Dr Martin Hall
07 Oct 2020
Advanced Oncotherapy
Life Sciences
Progress towards commissioning of first LIGHT
By
Dr Martin Hall
07 Oct 2020
Diurnal Group Plc
Life Sciences
And then there were three
By
Dr Martin Hall
30 Sep 2020
Arix Bioscience
Life Sciences
Realising the valuation disconnect
By
Dr Martin Hall
21 Sep 2020
Shield Therapeutics Plc
Life Sciences
Optimism over US deal
By
Dr Martin Hall
18 Sep 2020
Diurnal Group Plc
Life Sciences
Closely watching the regulators
By
Dr Martin Hall
17 Sep 2020
Diurnal Group Plc
Life Sciences
Flow of regulatory approvals
By
Dr Martin Hall
13 Aug 2020
Allergy Therapeutics plc
Life Sciences
Record sales and a COVID-19 wildcard
By
Dr Martin Hall
20 Jul 2020
Prev
1
...
4
5
6
7
8
...
22
Next
